Loading the session
Loading the session
Loading instrument
$43.84
+0.78%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:16 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +2.6% (SPY −2.6%, XLV +9.9%). 3 months: −11.4% (SPY −2.2%, XLV +13.5%). 1 year: −55.9% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BSX, SPY and XLV · as of 3 Nov 2026
Closed at $43.50 on 3 Nov 2026: 58.8% below the 52-week high of $105.65 (13 Nov 2025) and 9.9% above the low of $39.57 (28 Oct 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
28 Oct 2026 volume of 69.8M shares was 4.0× the average of the 30 sessions before it (17.5M), as the price fell 5.8%. SPY traded 0.7× its own average that session.
Daily volume against a 30-session baseline · as of 28 Oct 2026
The 3 Nov 2026 close of $43.50 was 2.4% below its 50-day average ($44.56) and 22.4% below its 200-day average ($56.07). It has closed below the 200-day for 242 sessions, since 17 Nov 2025. The 50-day average crossed below the 200-day on 16 Oct 2025, 263 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
40.7M shares were sold short at the 15 Oct 2026 settlement, 2.8% of the 1.45B shares outstanding; covering them would take 2.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 3 Nov 2026 close
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
May 27, 2026
−12.46%March 30, 2026
−9.02%February 4, 2026
−17.59%